Reversible dilated cardiomyopathy associated with amphotericin B therapy

Soares, Juliana Rodrigues; Nunes, Maria Carmo Pereira; Leite, Anderson Ferreira; Falqueto, Eduardo Belisário; Lacerda, B. E. R. A.; Ferrari, Teresa Cristina Abreu

doi:10.1111/jcpt.12237

Cited by 16 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Direct toxic cardiac damage is a rare adverse event, but reversible dilated cardiomyopathy associated with AmB treatment has been reported, especially in patients with a certain predisposing factor for heart failure. 27 Cumulative cardiotoxicity of SbV such as sodium antimony gluconate (SAG) and AmB has been reported, causing potential severe complications including sudden death. 28 The mechanism of this cardiotoxicity is not well-defined.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Leishmaniasis y corazón

Farina¹,

García-Martínez²,

Saldarriaga³

et al. 2021

ACM

View full text Add to dashboard Cite

As one of the neglected tropical diseases, leishmaniasis is defined as a parasitic communicable disease that is most prevalent in tropical and subtropical regions, affecting especially populations living in poverty. It has a profound negative impact on developing economies. It represents a group of heterogeneous syndromes with a wide spectrum of severity ranging from self-resolving cutaneous injuries to disseminated visceral compromise. Visceral leishmaniasis represents its most severe form, can affect almost all organs, and can have fatal consequences, especially in immunosuppressed patients. Cardiac involvement seems to be rare but has not been deeply studied. Consequently, there are no clear recommendations for the screening of cardiac manifestations in these patients. However, cardiovascular complications could be potentially lethal. In addition, there are valuable reports on the potential cardiotoxicity caused by drugs used in the treatment of this condition, so knowledge of its side effects could have important implications. This article is a part of the "Neglected Tropical Diseases and other Infectious Diseases affecting the Heart" project (the NET-Heart Project); its purpose is to review all the information available regarding cardiac implications of this disease and its treatment and to add knowledge to this field of study, focusing on the barriers for diagnosis and treatment, and how to adopt strategies to overcome them.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Leishmaniasis y corazón

Farina¹,

García-Martínez²,

Saldarriaga³

et al. 2021

ACM

View full text Add to dashboard Cite

show abstract

“…One patient was a 64-yr old man treated with LipAmb for febrile neutropenia that developed a severe global impairment of the left ventricular function with an ejection fraction (EF) of 13% that returned to 56% after discontinuation of the drug and a second patient was a 23-yr old woman with candiduria that after 8 days of LipAmb developed cardiac failure and an EF of 35% with a return to a near normal function after 1 month of drug withdrawal [4] . More recently, Soares et al described a 45-yr old man in Brazil that was treated with D-Amb for visceral leishmaniasis for 18 days that presented with cardiac failure after 5 days off the drug with a LVEF of 24% that reversed to normal after 1 month [5] . Table 1 presents these findings for patients with cardiomyopathy related to amphotericin B treatment.…”

Section: Discussionmentioning

confidence: 99%

Reversible cardiomyopathy secondary to Amphotericin-B

Bandeira

Filho²,

Ramos³

2016

Medical Mycology Case Reports

View full text Add to dashboard Cite

show abstract

“…In Appendix A we summarize the main/most used drugs and food supplements that can worsen the prognosis of heart failure patients; thus, it is recommended to avoid them by this category of patients [ 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 ,…”

Section: Drugs and Food Supplements That Can Aggravate Hfmentioning

confidence: 99%

An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure

Buda

Prelipcean

Cozma

et al. 2022

JCM

View full text Add to dashboard Cite

Since the prevalence of heart failure (HF) increases with age, HF is now one of the most common reasons for the hospitalization of elderly people. Although the treatment strategies and overall outcomes of HF patients have improved over time, hospitalization and mortality rates remain elevated, especially in developed countries where populations are aging. Therefore, this paper is intended to be a valuable multidisciplinary source of information for both doctors (cardiologists and general physicians) and pharmacists in order to decrease the morbidity and mortality of heart failure patients. We address several aspects regarding pharmacological treatment (including new approaches in HF treatment strategies [sacubitril/valsartan combination and sodium glucose co-transporter-2 inhibitors]), as well as the particularities of patients (age-induced changes and sex differences) and treatment (pharmacokinetic and pharmacodynamic changes in drugs; cardiorenal syndrome). The article also highlights several drugs and food supplements that may worsen the prognosis of HF patients and discusses some potential drug–drug interactions, their consequences and recommendations for health care providers, as well as the risks of adverse drug reactions and treatment discontinuation, as an interdisciplinary approach to treatment is essential for HF patients.

show abstract

Reversible dilated cardiomyopathy associated with amphotericin B therapy

Cited by 16 publications

References 18 publications

Leishmaniasis y corazón

Leishmaniasis y corazón

Reversible cardiomyopathy secondary to Amphotericin-B

An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure

Contact Info

Product

Resources

About